Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers

Fusobacterium nucleatum (FN) plays a pivotal role in the development and progression of colorectal cancer by modulating antitumor immune responses. However, the impact of FN on immune regulation in the tumor microenvironment has not been fully elucidated.The abundance of FN was measured in 99 stage III CRC tumor tissues using quantitative polymerase chain reaction. Gene expression profiles were assessed and annotated using consensus molecular subtypes (CMS), Gene Ontology (GO) analysis, and deconvolution of individual immune cell types in the context of FN abundance. Immune profiling for tumor infiltrating T cells isolated from human tumor tissues was analyzed using flow cytometry. Ex vivo tumor-infiltrating T cells were stimulated in the presence or absence of FN to determine the direct effects of FN on immune cell phenotypes.Gene expression profiles, CMS composition, abundance of immune cell subtypes, and survival outcomes differed depending on FN infection. We found that FN infection was associated with poorer disease-free survival and overall survival in stage III CRC patients. FN infection was associated with T cell depletion and enrichment of exhausted CD8+ and FoxP3+ regulatory T cells in the tumor microenvironment. The presence of FN in tumors was correlated with a suppressive tumor microenvironment in a T cell-dependent manner.FN enhanced the suppressive immune microenvironment with high depletion of CD8+ T cells and enrichment of FoxP3+ regulatory T cells in human colorectal cancer cases. Our findings suggest a potential association for FN in adaptive immunity, with biological and prognostic implications.

[1]  S. Bullman,et al.  Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer , 2022, Nature.

[2]  Di Wang,et al.  Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model , 2022, World journal of gastroenterology.

[3]  Yu-qin Mao,et al.  Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice , 2022, Gut microbes.

[4]  H. Qin,et al.  Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer , 2021, Signal Transduction and Targeted Therapy.

[5]  S. Paik,et al.  Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer , 2021, Scientific Reports.

[6]  O. Mandelboim,et al.  Fusobacterium nucleatum CbpF Mediates Inhibition of T Cell Function Through CEACAM1 Activation , 2021, Frontiers in Cellular and Infection Microbiology.

[7]  D. Longley,et al.  Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC) , 2021, Gut.

[8]  C. Huttenhower,et al.  Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment , 2021, Clinical Cancer Research.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  J. Galon,et al.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.

[11]  E. Elinav,et al.  Interaction between microbiota and immunity in health and disease , 2020, Cell Research.

[12]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[13]  Liwu Li,et al.  Fusobacterium nucleatum host cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration , 2020, bioRxiv.

[14]  D. Longley,et al.  Fusobacterium nucleatum in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[15]  Hoguen Kim,et al.  VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers , 2019, Science Immunology.

[16]  Kongming Wu,et al.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.

[17]  S. Zhang,et al.  Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer , 2019, Journal of experimental & clinical cancer research : CR.

[18]  W. Garrett,et al.  Fusobacterium nucleatum — symbiont, opportunist and oncobacterium , 2018, Nature Reviews Microbiology.

[19]  D. Bending,et al.  A temporally dynamic Foxp3 autoregulatory transcriptional circuit controls the effector Treg programme , 2018, bioRxiv.

[20]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[21]  A. York Microbiome: Fusobacterium persistence in colorectal cancer , 2017, Nature Reviews Microbiology.

[22]  Fangfang Guo,et al.  Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy , 2017, Cell.

[23]  A. Lin,et al.  FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma , 2017, Gut.

[24]  P. Laurent-Puig,et al.  Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Paik,et al.  Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype , 2017, Oncotarget.

[26]  Mingyang Song,et al.  Tumour CD274 (PD-L1) expression and T cells in colorectal cancer , 2016, Gut.

[27]  M. Hattori,et al.  Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.

[28]  Etienne Becht,et al.  Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy , 2016, Clinical Cancer Research.

[29]  R. Milo,et al.  Revised Estimates for the Number of Human and Bacteria Cells in the Body , 2016, bioRxiv.

[30]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[31]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[32]  Mingyang Song,et al.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis , 2015, Gut.

[33]  C. Huttenhower,et al.  Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. , 2015, JAMA oncology.

[34]  J. Meyerhardt,et al.  Role of physical activity and diet after colorectal cancer diagnosis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[36]  P. Goldberg,et al.  Quantitative Profiling of Colorectal Cancer-Associated Bacteria Reveals Associations between Fusobacterium spp., Enterotoxigenic Bacteroides fragilis (ETBF) and Clinicopathological Features of Colorectal Cancer , 2015, PloS one.

[37]  S. Jonjić,et al.  Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. , 2015, Immunity.

[38]  S. Ostrand-Rosenberg,et al.  The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity , 2014, The Journal of Immunology.

[39]  Y. Belkaid,et al.  Role of the Microbiota in Immunity and Inflammation , 2014, Cell.

[40]  Cynthia L Sears,et al.  Microbes, microbiota, and colon cancer. , 2014, Cell host & microbe.

[41]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[42]  M. R. Rubinstein,et al.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.

[43]  V. Tremaroli,et al.  Functional interactions between the gut microbiota and host metabolism , 2012, Nature.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[45]  A. Macpherson,et al.  Interactions Between the Microbiota and the Immune System , 2012, Science.

[46]  Herman Waldmann,et al.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.

[47]  B. Birren,et al.  Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. , 2012, Genome research.

[48]  Richard A. Moore,et al.  Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. , 2012, Genome research.

[49]  Shuji Ogino,et al.  Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.

[50]  Susan Kinder-Haake,et al.  Fusobacterium nucleatum Outer Membrane Proteins Fap2 and RadD Induce Cell Death in Human Lymphocytes , 2010, Infection and Immunity.